They are the: Phase III study of Exenatide in Parkinsons study in the UK Phase II study of Lixisenatide in Parkinsons study in France (reporting results in late 2022) Phase II study of Semaglutide in Parkinsons study in Norway Phase II study of NLY01 in Parkinsons study across the USA (being conducted by Neuraly reporting results in 2023) Phase II study of PT320 in Parkinsons in South Korea (being conducted by Peptron -reporting results in 2022) Phase II study of Exenatide trial in Parkinsons in Sweden Phase I study of Exenatide in Parkinsons study in Florida The recently completed trial is a Phase II study investigating the effects of liraglutide in people with Parkinsons
Set Realistic Expectations This is not a quick-fix drug
[1] TRICARE coverage for Zepbound splits into three categories as of November 2025: Key takeaway: If you have TRICARE Prime, Select, or related plans, Zepbound IS coveredbut you'll need to navigate prior authorization (PA, where your doctor must get approval before you can fill the prescription) and step therapy (trying lower-cost medications first)
Per HumeCare's own Medications Safety Information, compounded semaglutide is not FDA-approved, has not been reviewed by the FDA for safety, effectiveness, or manufacturing quality, and is not the same as, equivalent to, or interchangeable with the FDA-approved branded products
Know your source